Neuro-Ophthalmological Warning Signs in Intracranial Neoplasms: Clinical Patterns for Early Detection and Visual Preservation
DOI:
https://doi.org/10.64784/296Keywords:
Neuro-ophthalmology, intracranial neoplasms, brain tumors, visual loss, visual field defects, optic neuropathy, papilledema, diplopia, pituitary adenoma, meningioma, optical coherence tomography, magnetic resonance imaging, early diagnosisAbstract
Neuro-ophthalmological manifestations may represent the first clinically detectable sign of intracranial neoplasms, particularly when tumors involve the optic nerves, optic chiasm, sellar and parasellar regions, cranial nerves, skull base, brainstem, or structures associated with intracranial pressure. This study analyzed the main visual and ocular manifestations associated with intracranial tumors and their potential value for early diagnosis through a descriptive and analytical review of the scientific literature. Evidence concerning pituitary macroadenomas, meningiomas, optic pathway gliomas, craniopharyngiomas, and other intracranial neoplasms was examined, integrating clinical findings with automated perimetry, funduscopic examination, optical coherence tomography, and magnetic resonance imaging. The reviewed data showed a predominance of afferent visual abnormalities, particularly progressive visual loss, transient visual obscurations, visual-field defects, optic-disc changes, and optic neuropathy. Pituitary macroadenomas and meningiomas represented the most frequent tumor groups in the analyzed clinical series. Anatomical localization was closely associated with the pattern of neuro-ophthalmological involvement: sellar and suprasellar lesions were predominantly related to visual-field abnormalities, while lesions affecting the anterior cranial base or optic apparatus frequently produced structural optic nerve changes. Optical coherence tomography demonstrated the ability to identify retinal ganglion cell abnormalities in a subset of patients with MRI-confirmed chiasmal compression despite normal conventional visual fields, supporting the complementary role of structural assessment in early disease. Diagnostic intervals varied considerably, ranging from days to several years, and a substantial proportion of patients experienced visual symptoms for more than six months before definitive tumor identification. These findings indicate that persistent, progressive, unexplained, or anatomically suggestive visual abnormalities should raise suspicion of intracranial pathology. Integrating neuro-ophthalmological examination, functional testing, structural retinal assessment, and neuroimaging may shorten diagnostic delay, improve anatomical localization, facilitate timely multidisciplinary referral, and increase the probability of preserving visual function before irreversible axonal damage develops.
References
[1] C. R. Dermarkarian, A. T. Kini, B. A. Al Othman, and A. G. Lee, “Neuro-ophthalmic manifestations of intracranial malignancies,” J. Neuroophthalmol., vol. 40, no. 3, pp. e31–e48, 2020, doi: 10.1097/WNO.0000000000000950.
[2] N. Sefi-Yurdakul, “Visual findings as primary manifestations in patients with intracranial tumors,” Int. J. Ophthalmol., vol. 8, no. 4, pp. 800–803, 2015, doi: 10.3980/j.issn.2222-3959.2015.04.28.
[3] A.-L. Vié and G. Raverot, “Modern neuro-ophthalmological evaluation of patients with pituitary disorders,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 33, no. 2, Art. no. 101279, 2019, doi: 10.1016/j.beem.2019.05.003.
[4] M. T. M. Wang, J. A. Meyer, and H. V. Danesh-Meyer, “Neuro-ophthalmic evaluation and management of pituitary disease,” Eye, vol. 38, no. 12, pp. 2279–2288, 2024, doi: 10.1038/s41433-024-03187-x.
[5] J. S. Xie, L. Donaldson, and E. Margolin, “Papilledema: A review of etiology, pathophysiology, diagnosis, and management,” Surv. Ophthalmol., vol. 67, no. 4, pp. 1135–1159, 2022, doi: 10.1016/j.survophthal.2021.11.007.
[6] T. Wang, J. Kim, M. Masotti, and J. D. Trobe, “MRI indicators of papilledema in brain tumors,” J. Neuroophthalmol., vol. 45, no. 4, pp. 453–459, 2025, doi: 10.1097/WNO.0000000000002342.
[7] V. P. Douglas, K. A. A. Douglas, and D. M. Cestari, “Optic nerve sheath meningioma,” Curr. Opin. Ophthalmol., vol. 31, no. 6, pp. 455–461, 2020, doi: 10.1097/ICU.0000000000000700.
[8] C. S. Eddleman and J. K. Liu, “Optic nerve sheath meningioma: Current diagnosis and treatment,” Neurosurg. Focus, vol. 23, no. 5, Art. no. E4, 2007, doi: 10.3171/FOC-07/11/E4.
[9] S. Dal Bello et al., “The present and future of optic pathway glioma therapy,” Cells, vol. 12, no. 19, Art. no. 2380, 2023, doi: 10.3390/cells12192380.
[10] Y. Sasagawa, M. Nakahara, D. Takemoto, and M. Nakada, “Optical coherence tomography detects early optic nerve damage before visual field defect in patients with pituitary tumors,” Neurosurg. Rev., vol. 46, no. 1, Art. no. 85, 2023, doi: 10.1007/s10143-023-01990-w.
[11] R. J. Blanch, J. A. Micieli, N. M. Oyesiku, N. J. Newman, and V. Biousse, “Optical coherence tomography retinal ganglion cell complex analysis for the detection of early chiasmal compression,” Pituitary, vol. 21, no. 5, pp. 515–523, 2018, doi: 10.1007/s11102-018-0906-2.
[12] J. A. Micieli, N. J. Newman, and V. Biousse, “The role of optical coherence tomography in the evaluation of compressive optic neuropathies,” Curr. Opin. Neurol., vol. 32, no. 1, pp. 115–123, 2019, doi: 10.1097/WCO.0000000000000636.
[13] H. V. Danesh-Meyer, J. J. Yoon, M. Lawlor, and P. J. Savino, “Visual loss and recovery in chiasmal compression,” Prog. Retin. Eye Res., vol. 73, Art. no. 100765, 2019, doi: 10.1016/j.preteyeres.2019.06.001.
[14] S. Ogra, A. D. Nichols, S. Stylli, A. H. Kaye, P. J. Savino, and H. V. Danesh-Meyer, “Visual acuity and pattern of visual field loss at presentation in pituitary adenoma,” J. Clin. Neurosci., vol. 21, pp. 735–740, 2014, doi: 10.1016/j.jocn.2014.01.005.
[15] K. Schmalisch, M. Milian, T. Schimitzek, W. A. Lagrèze, and J. Honegger, “Predictors for visual dysfunction in nonfunctioning pituitary adenomas—Implications for neurosurgical management,” Clin. Endocrinol., vol. 77, no. 5, pp. 728–734, 2012, doi: 10.1111/j.1365-2265.2012.04457.x.
[16] M. A. Nuijts et al., “Visual functions in children with craniopharyngioma at diagnosis: A systematic review,” PLoS ONE, vol. 15, no. 10, Art. no. e0240016, 2020, doi: 10.1371/journal.pone.0240016.
[17] R. Colliander, S. Sharma, N. A. Shlobin, L. G. Fernandez, M. A. LoPresti, S. Lam, and M. DeCuypere, “Visual outcomes after treatment of craniopharyngioma in children: A systematic review,” Childs Nerv. Syst., vol. 40, no. 6, pp. 1641–1659, 2024, doi: 10.1007/s00381-024-06328-5.
[18] N. Margalit, T. Shahar, G. Barkay, L. Gonen, E. Nossek, U. Rozovski, and A. Kesler, “Tuberculum sellae meningiomas: Surgical technique, visual outcome, and prognostic factors in 51 cases,” J. Neurol. Surg. B Skull Base, vol. 74, no. 4, pp. 247–258, 2013, doi: 10.1055/s-0033-1342920.
[19] D. O’Connor et al., “Optic pathway glioma in adults: A systematic review and individual patient-level analysis of clinical characteristics and prognostic factors,” Cancers, vol. 18, no. 8, Art. no. 1225, 2026, doi: 10.3390/cancers18081225.
[20] V. S. Chhabra and N. J. Newman, “The neuro-ophthalmology of pituitary tumors,” Compr. Ophthalmol. Update, vol. 7, no. 5, pp. 225–240, 2006.
